### Welcome to Today's Webinar Hosted by











Today's webinar is funded in part by a cooperative agreement (U52MC04391) with the Maternal and Child Health Bureau (MCHB) of the Health Resources and Services Administration (HRSA) at the United States Department of Health and Human

#### cmv.usu.edu



# THE WESTIN HOTEL OTTAWA ONTARIO CANADA



# AUGUST 22ND AUGUST 24TH

cmv.usu.edu

# Parent Story Randi Bond



### Universal Congenital Cytomegalovirus Screening: Experiences of Newborn Saliva Collection from Five Minnesota Hospitals

Emily Graupmann, BA and Whitney Wunderlich, MA



# Agenda

- Introductions
- Minnesota cCMV study
- Collection methods and process
- Logistical considerations
- Social considerations and parent questions
- Other considerations
- Saliva at the lab
- Saliva accuracy
- Procedural advantages and disadvantages of newborn saliva swab collection
- Methods for improving saliva collection


### Introductions

#### Presenters:

Emily Graupmann, BA
 University of Minnesota



Whitney Wunderlich, MA
 Allina Health



#### Important acknowledgments

- Principal Investigator: Mark R. Schleiss, MD
- CDC Co-Principal Investigator: Sheila Dollard, PhD
- University of Minnesota Team: Elizabeth Tepozteco, Jenna Wassenaar, BS, CCRP, Sagal Jama
- University of Minnesota Lab: Nelmary Hernandez-Alvarado, MS
- **Allina Health Team**: Cecely Hoyt, MPH, Anna Schulte, MPH, Jessica Taghon, MHA, Abbey Sidebottom, PhD, MPH
- Minnesota Department of Health: Sondra Rosendahl, MS, CGC, Kirsten Coverstone, AuD

# Introduction to Minnesota cCMV universal screening study

#### Purpose

 Address the clinical sensitivity of PCR performed on the newborn dried blood spot (DBS) versus PCR performed on saliva specimens in the context of <u>universal newborn screening</u>





# Introduction to Minnesota cCMV universal screening study

#### Structure and Partnerships

- Prospective study
- Data collection at 5 Minnesota hospitals

#### **Funding**

CDC and University of Minnesota







## Study Enrollment to Date

#### As of March 2020:

- Enrolled 15,697
- Enrollment Rate 70%

#### **Positive cases:**

- •86 positives
- •70 confirmed



## Collection Methods

> Saliva



> Blood





## Saliva Collection Process



- Wash hands
- Don gloves
- Place swab between the gum line and wall of the cheek
- Turn for 5 seconds on the first side
- Place swab between the gum line and wall of the cheek on the opposite side
- Turn for 5 seconds on the second side
- Snap off swab end in labeled microtainer

- Indicate if baby has fed in the last 30 minutes by checking box labeled "fed 30 min"
- Place microtainer in drying kit (box with microtainer rack, desiccant, and humidity indicator)
- Leave microtainer open, allow to dry at least 1 hour
- Close microtainer top, remove microtainer from drying kit, and place in bag for transport to lab

# Saliva Collection-Logistical Considerations

Setting

Timing of collection

Supplies


# Logistical Considerations - Setting

#### **Data collection sites**

- Postpartum
- •NICU


#### **Storage of samples**

- Secure
- No patient identifiers



# Logistical Considerations-Timing

- Newborns are typically in the hospital between 24 and 72 hours
- Wait time after newborn feeding
- Sample dry time
- Transportation







# Logistical Considerations-Supplies

### Supplies:

- Individually wrapped sterile swabs
- Microliter containers
- Study labels
- Humidity strips/desiccant packets
- Provided from central UMN lab
- Swab types



## Saliva Collection: Social Considerations

#### Parent reactions

- Postpartum
- NICU
- Non-English speaking families
- Parent questions





## Saliva Collection: Social Considerations

#### Non-English speaking families

- Spanish and Somali speakers are most common among our study
- Use of interpreter services
- Cultural differences for consideration

#### Waraaqda Oggolaanshaha ee Gaaban si Looga Qaybgalo Cilmi-baadhis Waxa lagu weydiisanayaa inad ka soo qaybgashid daraasad cilmi-baadhis. Ka-hor inta aanad oggolaan inad ka gaybgashid daraasadda, waa muhiim inad daraasadda ka heshid sharaxaad cad oo ah lugad ad fahmi kartid. Halkan hoose waxa ku taxan waxa ad oggolaanaysid marka ad saxeexdid waraagdan oggolaanshaha. Turjubaan ka mid ah baadheyaasha wada daraasadda ama ka tirsan wakiiladooda ayaa kuu sharaxay waxyaabahan: ujeedooyinka cilmi-baadhista, habraacyada, iyo mudda ay socon doonto cilmi-baadhistu wixii ah habraacyo ah tijaabin wixii ah halisyo la sii arki karo oo caqli-gal ah (halisyada suurtogal ah ee hadda la yaqaano), raaxo-darooyinka iyo anfacvada cilmi-baadhista wixii ah habraacyo ama daweyn ah beddelaad anfac leh; iyo sida garsoodinimada loo illaalin doong Haddii ay khuseyso daraasaddan, waxa wax lagaaga sheegay waxyaabahan wixii ah magdhow la heli karo ama la-tacaalis caafimaad haddii ad ku dhaawacantid cilmi-baadhista; suurtogalnimada halisyo aan hore arki karin (halisyo aan hadda la agoon): xaaladaha u baadhuhu ku joojin karo ka qaybgalkaaga; wixii ah kharashyo adiga ku soo gaadhaya; waxa dhacaya haddii ad go'aansatid inad joojisid ka qaybgalka; goorta laguu sheegi doono natiijooyin cusub oo laga yaabo inay saameeyaan oggolaanshahaaga inad ka 7. inta qof ee ku jiri doona daraasadda , oo ah Baadhaha Koobaad (Principal Investigator) (PI Waxa laguu sheegay inad la xidhiidhi kartid oo ad ka wici kartid , haddii ad qabtid su'aalo ku saabsan darasaadda ama dhibaatooyin ku qabtid daraasadda waxa kale oo ad la xidhiidhi kartaa Xafiiska Maamuulka ee Guddida Dib-u-fiirinta (Allina Health Institutional Review Board Administration Office) on lambarkoodu vahay 612-262-4920 haddii ad gabtid wax su'aalo ah oo ku saabsan xuguugdaada ka-gaybgale cilmi-baadhis ahaan, daraasadda cilmi-baadhista, ama wixii ad sameyn lahayd haddii ad dhaawacantid Waxa laguu sheegay in ka-qaybgalkaaga cilmi-baadhistan u yahay ikhtiyaar iyo in aan lagu ganaaxi doonin ama aanay kaa lumi doonin anfacyo haddii ad diidid inad ka qaybgashid ama go'aansatid inad joojisid ka-dib marka ad oggolaatid inad Haddii ad oggolaatid inad ka qaybgashid, waxa laguu sheegay in lagu siin doono nuqul ama koobi ah dukumentigan oo Saxeexidda dukumentigan macnaheedu waxa weeye in daraasadda cilmi-baadhista, oo u ku jiro macluumaadka sare, laguugu sharaxay af ahaan, iyo inad si ikhtiyaar ah u oggolaatay inad ka qaybgashid. Saxeexa Ka-qaybgalaha/Wakiilka Sharci ee Amar Haysta/Waxa la Isu Yahay Taariikh & Wakhti Saxeexa Markhaatiga Taariikh & Wakhti



## Parent Questions

#### **About the virus**

- •Is this a new virus? Why have I never heard of it?
- •What is the importance of being screened? Why is my child not already screened?
- •If the mother passes CMV to her baby, why is she not tested?

#### **About the sample/collection**

- •Will it hurt my baby?
- •If my baby has an antibiotic can you still take the swab?
- •Can my pediatrician do the test instead?
- •Are you collecting DNA?

#### **About the test**

- •What if one sample tests positive and the other does not?
- •Will my health conditions show up on the test? (ex. herpes)
- •How effective is testing of the sample?

#### Sample storage and use

- •Will the samples be stored in a database?
- •What will happen with the sample? Is it used for future research?

## Saliva Collection: Social Considerations


- Nursing unit interactions
  - Education
    - Large number of staff
    - Different shifts
    - Nurse turnover
  - Work flow
  - Communication
  - Universal screening-saliva collection




## Other considerations

- Humidity
  - Cause for discolored samples?
  - Desiccant packets
- Spacing of samples







### Other considerations

- Possible sample impurities
  - Sweet-ease
  - Blood
  - Medications (antibiotics)
  - Donor milk/formula/breastmilk
- Documentation of 'abnormal' swabs
  - Overall rare, but worth mentioning














## Saliva at the lab

- Shipping Methods
- Containers
- Testing
  - PCR
  - All samples tested at a central lab (UMN)
- CDC quality control



# Saliva accuracy

Total Enrolled = 15,687

Confirmed Cases = 70

- 10 saliva only
- 5 DBS only; negative saliva

Detection rate saliva only: 65/70 = 92.9%

Prevalence of cCMV among all samples:

70/15,687 = 0.45%

# Advantages/Disadvantages of Saliva Collection

- -Family acceptance
- -Non-invasive
- -Fast collection
- -High detection rate

- -Collection variability
- -Shipping logistics for larger scale collection
- False positives
- -Positive screens for healthy infants
- -Testing scalability for NBS programs

# Tips for improving saliva collection

- Communication
- Consistency
- Attention to detail
- Focus on messaging around the importance of screening

# Questions?



#### cmv.usu.edu



# THE WESTIN HOTEL OTTAWA ONTARIO CANADA



# AUGUST 22ND AUGUST 24TH

cmv.usu.edu

### Your feedback is important!

# Click Here to Give Us Feedback & Get Your Certificate of Attendance



The National Technical Resource Center for Early Hearing Detection and Intervention (EHDI) Programs